Clinical trial
Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at…
NCT00184691 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00184691 |
|---|---|
| Title | Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 Years |
| Official title | Controlled Study to Evaluate the Efficacy and Safety of the Treatment With Growth Hormone Which Will be Started Randomly at the Ages of 2 to 5, in Children Diagnosed of IUGR |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Foetal Growth Problem, Small for Gestational Age |
| Intervention type | Drug |
| Interventions | somatropin |
| Enrollment | 78 |
| Start date | Apr 1, 1999 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Sep 16, 2005 |
| Last update posted | Jan 18, 2017 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: